Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice.
Carnicer R, Guillén N, Arbonés-Mainar JM, Navarro MA, Guzmán MA, Barranquero C, Arnal C, Gascón S, Acín S, Mourelle M, Osada J.
Carnicer R, et al. Among authors: osada j.
Naunyn Schmiedebergs Arch Pharmacol. 2009 May;379(5):489-500. doi: 10.1007/s00210-008-0377-5. Epub 2008 Dec 3.
Naunyn Schmiedebergs Arch Pharmacol. 2009.
PMID: 19050853